Clinical Trial: AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07611110) titled 'AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)' on April 22.

Brief Summary: The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

Study Start Date: May 04

Study Type: INTERVENTIONAL

Condition: Metastatic Castration-resistant Prostate Cancer

Intervention: DRUG: AZD2265

IV

DRUG: Cabazitaxel

IV in combination with oral prednisone/prednisolone

DRUG: Abiraterone

Oral in combination with predn...